Skip to main content
Clinical Trials/NCT04682184
NCT04682184
Completed
N/A

A Study to Investigate Continuous Heart Rate Monitoring Using a Chest-worn Biosensor on the Background of Drug-induced Positive and Negative Heart Rate Changes

Eli Lilly and Company1 site in 1 country21 target enrollmentJanuary 27, 2021

Overview

Phase
N/A
Intervention
Propranolol
Conditions
Healthy
Sponsor
Eli Lilly and Company
Enrollment
21
Locations
1
Primary Endpoint
The mean change in heart rate (HR)
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The main purpose of this study in healthy participants is to find out whether a heart rate monitor will accurately pick up changes in heart rate caused by 2 different medications (pseudoephedrine and metoprolol), on the background of daily activities. Participants will wear a patch heart rate and activity monitor on the chest for the entire study. The study will last about 36 days and may include up to seven visits to the study center.

Registry
clinicaltrials.gov
Start Date
January 27, 2021
End Date
March 25, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Are overtly healthy males or females
  • Have a body mass index (BMI) of 18.0 to 35 kilograms/square meter (kg/m2), inclusive at screening
  • Have blood pressure, pulse rate, blood and urine laboratory test results that are acceptable for the study
  • Have given written informed consent approved by Lilly and the ethical review board governing the site

Exclusion Criteria

  • Have or used to have health problems that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
  • Have history of sensitive skin or chronic skin conditions, like eczema
  • Regularly use known drugs of abuse
  • Are women who are pregnant or lactating
  • Have known allergies to medications used in the study

Arms & Interventions

Wearable Biosensor Patch Device + Propranolol

Participants will wear the biosensor patch device followed by propranolol administered orally in one of three study periods.

Intervention: Propranolol

Wearable Biosensor Patch Device + Propranolol

Participants will wear the biosensor patch device followed by propranolol administered orally in one of three study periods.

Intervention: Wearable Biosensor Patch Device

Wearable Biosensor Patch Device + Pseudoephedrine

Participants will wear the biosensor patch device followed by pseudoephedrine administered orally in one of three study periods.

Intervention: Pseudoephedrine

Wearable Biosensor Patch Device + Pseudoephedrine

Participants will wear the biosensor patch device followed by pseudoephedrine administered orally in one of three study periods.

Intervention: Wearable Biosensor Patch Device

Wearable Biosensor Patch Device (Alone)

Participants will wear biosensor patch device (alone) during one of three study periods.

Intervention: Wearable Biosensor Patch Device

Outcomes

Primary Outcomes

The mean change in heart rate (HR)

Time Frame: Day 1: Hour 1, Hour 4 post intervention

The mean change in HR

Study Sites (1)

Loading locations...

Similar Trials